AARTIPHARM Aarti Pharmalabs Q2 FY26 results (Jul–Sep 2025) and concall
Aarti Pharmalabs reported an 11% YoY increase in standalone revenue for Q2 FY26, driven by strong performance in Xanthine and CDMO-CMO segments. However, profitability was impacted by margin pressure in the API business and a significant Forex loss. The company is progressing with its Atali plant commissioning and Xanthine capacity expansion, while revising its full-year EBITDA growth guidance to 8-12%.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 8.7%, net profit down 49.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 458 | 538 | 564 | 386 | 418 −9% |
| EBITDA | 94 | 129 | 146 | 93 | 74 −21% |
| Net profit | 55 | 74 | 88 | 50 | 28 −49% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
